EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19

Dan Ma, Ximin Wang, Min Li, Chujiao Hu, Lei Tang

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110485 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Dan Ma und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, GuiZhou, China; Guizhou Provincial Engineering Technolog…. Hauptthemen laut MEDLINE: COVID-19, Severe acute respiratory syndrome-related coronavirus. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Periodic pandemics of coronavirus (CoV)-related pneumonia have been a major challenging issue since the outbreak of severe acute respiratory syndrome (SARS) in 2002 and Middle East respiratory syndrome (MERS) in 2012. The ongoing pandemic of CoV disease (COVID-19) poses a substantial threat to public health. As for the treatment options, only limited antiviral agents have been approved hitherto, and clinicians mainly focus on currently available drugs including the conventional antiviral interferons (IFNs). In clinical practice, IFNs, when used either alone or in combination with ribavirin and/or lopinavir/ritonavir, have shown promising outcomes, to some extent, in SARS-CoV or MERS-CoV treatment. Although the efficacy and safety of IFNs in COVID-19 treatment remain unclear, their possible use merits further evaluation. We present a review that summarizes current evidence of IFN treatment for COVID-19 and elaborates on other challenges in terms of the timing of IFN treatment initiation, treatment duration, and IFN type to be used. The review findings suggested that IFN acts by directly inhibiting viral replication and activating immune cell subsets. However, there is a lack of well-designed and controlled clinical trials providing firm evidence for the efficacy or safety of IFN therapy for CoVs. Additionally, critically ill patients with multiple immunosuppression-associated comorbidities may not benefit from IFN therapy, necessitating screening of those patients who would most benefit from IFN treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Severe acute respiratory syndrome-related coronavirusHumansInterferonsCOVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsLopinavir

Stichwörter der Autor:innen

CoronavirusEfficacyInterferonPneumoniaViral replication

Substanzen

InterferonsAntiviral AgentsLopinavir

Autor:innen und Institutionen

  • Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, GuiZhou, China; Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, G…
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.
  • Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang 550004, GuiZhou, China. Electronic address: huchujiao123@163.com.
  • Guizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang 550004, GuiZhou, China. Electronic address: tanglei19742022@163.com.

Zitieren

APA

Ma, D., Wang, X., Li, M., Hu, C., & Tang, L. (2023). Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110485

Vancouver

Ma D, Wang X, Li M, Hu C, Tang L. Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110485

BibTeX
@article{Ma2023,
  author = {Ma, Dan and Wang, Ximin and Li, Min and Hu, Chujiao and Tang, Lei},
  title = {Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110485}
}
Kostenlos starten →